Actively Recruiting

Phase 3
Age: 6Years - 14Years
All Genders
ID07029828

A Long-Term, Double-Blind Extension Study to Investigate the Safety and Efficacy of Ritlecitinib in Children With Severe Alopecia Areata Who Previously Completed Studies B7981027 or B7981031

Led by Pfizer · Updated on 2026-04-28

140

Participants Needed

41

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the long-term safety and effects of ritlecitinib, an oral medicine, for children with severe alopecia areata, a condition that causes significant hair loss. This Phase 3 trial focuses on participants who completed previous Pfizer studies and have notable scalp hair loss or specific vaccination history. The study aims to understand how well ritlecitinib is tolerated and its impact on hair regrowth and quality of life over time. Participants will take ritlecitinib capsules once daily at home for up to three years. Those who previously received different doses of ritlecitinib will continue the same dose, while others will be randomly assigned to either a higher or lower dose. Dose adjustments and treatment continuation will be evaluated at specific months, with some participants switched to placebo if they do not meet efficacy criteria, though they remain in the study. During the trial, participants will attend 17 clinic visits and receive monthly phone calls. Researchers will monitor safety by tracking adverse events and assess effectiveness using tools like the Severity of Alopecia Tool (SALT), eyebrow and eyelash assessments, and patient-reported outcomes on anxiety, depression, behavior, and quality of life. The study includes ongoing safety checks and measures cognitive function at select points, ensuring thorough evaluation throughout the three-year participation period.

CONDITIONS

Brief Title

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

Who Can Participate

Age: 6Years - 14Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with alopecia areata (including alopecia totalis and alopecia universalis) who completed studies B7981027 or B7981031.
  • For participants from Study B7981031: at least 50% scalp hair loss (SALT score of 50 or higher) at Screening and Baseline visits.
  • Received two doses of varicella vaccine or had varicella zoster virus infection before based on blood tests.
Not Eligible

You will not qualify if you...

  • Safety events requiring permanent discontinuation during or after Study B7981027 if the last dose was within 30 days before this study.
  • Participants who discontinued Study B7981027 for reasons other than safety must have resolved those issues before enrolling.
  • Safety events requiring permanent discontinuation during or after Study B7981031 or if last dose of Study B7981027 was more than 30 days prior.
  • Any current or past malignancies or lymphoproliferative disorders.
  • Untreated or inadequately treated active or latent tuberculosis infection.
  • History of severe or serious cytomegalovirus, herpes zoster, disseminated herpes simplex infections.
  • Infection with hepatitis B or hepatitis C virus.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Participants must have completed previous studies B7981027 or B7981031 and meet specific health criteria to enroll.

Treatment

Duration - Up to 3 years

Participants receive daily oral capsules of ritlecitinib at either a higher or lower dose for up to 3 years. Those who do not meet treatment continuation criteria at scheduled assessments may be switched to placebo but will remain in the study.

Visits occur at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36 for assessments and treatment continuation evaluation.

Trial Site Locations

Total: 41 locations

1

California Dermatology & Clinical Research Institute

Encinitas, California, United States, 92024

Actively Recruiting

2

Pediatric Skin Research

Miami, Florida, United States, 33156

Actively Recruiting

3

D&H Tamarac Research Center

Tamarac, Florida, United States, 33321

Not Yet Recruiting

4

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States, 46250

Actively Recruiting

5

Kindred Hair and Skin Center

Marriottsville, Maryland, United States, 21104

Not Yet Recruiting

6

Michigan Dermatology Institute

Waterford, Michigan, United States, 48328

Not Yet Recruiting

7

Ear, Nose & Throat Consultants, LLC

Omaha, Nebraska, United States, 68144

Actively Recruiting

8

Skin Specialists, PC dba Schlessinger MD

Omaha, Nebraska, United States, 68144

Actively Recruiting

9

Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist)

Papillion, Nebraska, United States, 68046

Actively Recruiting

10

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, United States, 87102

Actively Recruiting

11

University of New Mexico-IDS Pharmacy

Albuquerque, New Mexico, United States, 87106

Actively Recruiting

12

Regents of the University of New Mexico

Albuquerque, New Mexico, United States, 87131

Actively Recruiting

13

Equity Medical, LLC

The Bronx, New York, United States, 10455

Not Yet Recruiting

14

Northwest Dermatology Institute

Portland, Oregon, United States, 97210

Actively Recruiting

15

Penn State Health Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States, 17033

Not Yet Recruiting

16

Medical University of South Carolina Department of Dermatology and Dermatologic Surgery

Charleston, South Carolina, United States, 29425

Not Yet Recruiting

17

3A Research

El Paso, Texas, United States, 79902

Actively Recruiting

18

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States, 78218

Actively Recruiting

19

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

20

Prof. MUDr. Petr Arenberger, DrSc., MBA

Prague, Czechia, 11000

Not Yet Recruiting

21

Hospices Civils de Lyon - Hopital Femme Mere Enfant

Bron, France, 69500

Not Yet Recruiting

22

CHU de Dijon Bourgogne

Dijon, France, 21079

Not Yet Recruiting

23

GHICL - Service d'investigation - Recherche clinique

Lille, France, 59000

Not Yet Recruiting

24

Hôpital Saint Vincent de Paul

Lille, France, 59020

Not Yet Recruiting

25

Centre Hospitalier Universitaire de Nice

Nice, France, 06202

Not Yet Recruiting

26

Hôpitaux Drôme Nord

Romans-sur-Isère, France, 26100

Not Yet Recruiting

27

Centre Hospitalier Universitaire de Toulouse - Hôpital Larrey

Toulouse, France, 31400

Not Yet Recruiting

28

Tohoku University Hospital

Sendai, Miyagi, Japan, 980-8574

Not Yet Recruiting

29

Hamamatsu University Hospital

Hamamatsu, Shizuoka, Japan, 431-3192

Actively Recruiting

30

Kyorin University Hospital

Mitaka, Tokyo, Japan, 181-8611

Not Yet Recruiting

31

Osaka Metropolitan University Hospital

Osaka, Japan, 545-8586

Actively Recruiting

32

Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

Wroclaw, Lower Silesian Voivodeship, Poland, 50-566

Not Yet Recruiting

33

DERMEDIC Iwona Zdybska

Lublin, Lublin Voivodeship, Poland, 20-607

Not Yet Recruiting

34

Klinika Osipowicz & Turkowski

Warsaw, Masovian Voivodeship, Poland, 00-716

Not Yet Recruiting

35

Państwowy Instytut Medyczny MSWiA

Warsaw, Masovian Voivodeship, Poland, 02-507

Not Yet Recruiting

36

Provita Poliklinika

Warsaw, Masovian Voivodeship, Poland, 02-647

Not Yet Recruiting

37

Klinika Ambroziak Dermatologia

Warsaw, Masovian Voivodeship, Poland, 02-953

Not Yet Recruiting

38

Royalderm Agnieszka Nawrocka

Warsaw, Masovian Voivodeship, Poland, 02-962

Not Yet Recruiting

39

Centrum Medyczne Angelius Provita

Katowice, Silesian Voivodeship, Poland, 40-611

Not Yet Recruiting

40

Uniwersytecki Szpital kliniczny im. F. Chopina w Rzeszowie

Rzeszów, Poland, 35-055

Not Yet Recruiting

41

Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

Lodz, Łódź Voivodeship, Poland, 90-436

Not Yet Recruiting

Loading map...

Research Team

P

Pfizer CT.gov Call Center

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Korean Post Marketing Surveillance for Litfulo Capsule in Se...

Severe Alopecia Areata

Actively Recruiting

1 location

A Phase 3 Study to Investigate the Safety and Effectiveness ...

Severe Alopecia Areata

Actively Recruiting

80 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here